MedTrace Logo

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

NCT04195828 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2025-04-01

No results posted yet for this study

Summary

To evaluate the clinical efficacy and safety of camrelizumab combined with apatinib mesylate, nab-paclitaxel and S-1

Conditions

  • Advanced Gastric Cancer

Interventions

DRUG

Camrelizumab

Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg.

DRUG

Apatinib Mesylate

Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday。

DRUG

nab-paclitaxel

nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2.

DRUG

S1

S-1 was calculated according to body surface area , P.O., bid, d1-d14。And the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time

Sponsors & Collaborators

  • Fujian Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-18
Primary Completion
2022-07-22
Completion
2025-03-24

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04195828 on ClinicalTrials.gov